ROCKVILLE, Md., January 13, 2026 — BrainScope, a commercial-stage medical neurotechnology company applying AI and deep learning to computational neuroscience to deliver clinically validated, noninvasive digital tools for objective brain health assessment, today announced the appointment of Emily Baxi, Ph.D., Melanie Leitner, Ph.D., Edward Michelson, M.D., José Hernan N. Posas III, M.D., Jose Javier Provencio, M.D., and Genevieve Stein-O’Brien, Ph.D., to its Advisory Board. The appointments come at a pivotal time for BrainScope, as it scales its commercial footprint and expands its deep learning platform into new clinical indications, including neurodegenerative diseases and stroke.
“As we continue pioneering new frontiers in neurodiagnostics, we prioritize finding leaders who bring both deep technical and clinical knowledge along with a broad vision for the future of patient care,” said Matt Adams, chief executive officer of BrainScope. “We are incredibly fortunate to have Drs. Baxi, Leitner, Michelson, Posas, Provencio and Stein-O’Brien join us, and I am certain their guidance will be a catalyst for BrainScope’s continued innovation.”
Emily Baxi, Ph.D., is a director with the Science Philanthropy Accelerator for Research and Collaboration (SPARC) team at Milken Institute Strategic Philanthropy and brings a wealth of experience in science philanthropy. As a neuroscientist and educator, she advises foundations and philanthropists on the state of research to empower impactful giving, and leads large-scale research infrastructure initiatives such as the Integrated Network for Breakthrough Discoveries for bipolar disorder. Prior to her current role, she served as the executive director of the Packard Center for ALS (amyotrophic lateral sclerosis) Research at Johns Hopkins University and the program director for Answer ALS.
Melanie Leitner, Ph.D., currently serves as the chief scientific officer of the
ALS Investment Fund, a social impact venture capital fund investing in disease-modifying therapies for neurodegeneration. With nearly two decades of experience in the neuroscience translational space, Dr. Leitner has consulted for over 35 organizations across Alzheimer’s, Parkinson’s and ALS. She was part of the original ALS program team at Biogen and led the team that received the 2022 Healey International Prize for Innovation for the development of the PRO-ACT database, the largest clinical trial dataset in ALS.
Edward Michelson, M.D., is professor and chair of the Department of Emergency Medicine, Paul L. Foster School of Medicine, Texas Tech University
Health Sciences Center, El Paso. He earned a B.S. in biomedical engineering from MIT and an M.D. from Washington University School of Medicine in St. Louis and completed a combined residency in internal medicine and emergency medicine at Northwestern University in Chicago. Over a 39-year academic career at five major medical schools and centers, Dr. Michelson has collaborated with BrainScope on multiple research projects for more than 15 years, including scientific publications and national meeting presentations.
José Hernan N. Posas III, M.D., is a sports neurologist in the University of Virginia School of Medicine’s Department of Neurology in Charlottesville,
where he serves as vice chair for education and associate program director for the neurology residency, and serves on the Neurology Community Committee. His work spans medical education, community engagement, and concussion clinical care and research. At UVA, he helped develop and launch a Resident and Fellow Leadership Course with the UVA Health Leadership Institute. Nationally, he serves on the American Academy of Neurology Board of Directors and the editorial board of Continuum, and moderates and hosts the NeuroPanels educational webinar series. He earned his medical degree at LSU Health Sciences Center in New Orleans and completed neurology residency training at the University of Miami/Jackson Memorial Hospital, followed by a sports neurology fellowship at Kerlan Jobe Orthopaedic Clinic.
Jose Javier Provencio, M.D., currently serves as the division head of the hospital neurology division and the Louise Nerancy Professor in Neurology at
the University of Virginia, where he is also the medical director of the Nerancy Neuroscience Intensive Care Unit. A prominent translational researcher focused on the inflammatory underpinnings of acute brain injuries, Dr. Provencio holds national leadership roles on the steering committee of the Curing Coma Campaign and the annual program committee of the Society of Critical Care Medicine. He has dedicated his career to improving outcomes for patients with acute neurological conditions through both clinical excellence and innovative research.
Genevieve Stein-O’Brien, Ph.D., is the Terkowitz Family Rising Professor of Brain Science and Bloomberg Assistant Professor of Neuroscience at Johns
Hopkins University, with affiliations to the Kavli Neuroscience Discovery Institute, the McKusick-Nathans Department of Genomic Medicine, the Convergence Institute, and the Institute for Data Intensive Engineering and Science. She earned a Ph.D. in human genetics from the Johns Hopkins School of Medicine and an M.H.S. in biostatistics from the Johns Hopkins Bloomberg School of Public Health. Dr. Stein-O’Brien’s research focuses on computational and statistical methods for pattern detection and data integration in high-throughput omics data, including transfer learning approaches applied to single-cell transcriptional data to identify molecular co-regulation patterns across measurement types, tissues, and species.
The addition of these experts further strengthens BrainScope’s ability to develop novel digital biomarkers and expands the clinical utility of electroencephalography (EEG) to aid in diagnosing and monitoring a wide range of brain-related conditions. BrainScope is the first medical device to receive U.S. Food and Drug Administration (FDA) clearance in neurology using a machine learning approach. Its recently developed deep learning platform utilizes a Large Neural Model approach to transform how brain injuries and neurological diseases are assessed and managed through noninvasive, objective diagnostic tools.
About BrainScope
BrainScope is a commercial-stage medical neurotechnology company focused on applying artificial intelligence to brain electrical activity to develop noninvasive, objective diagnostic tools for brain health. With an FDA-cleared product already in commercial use and a robust machine and deep learning platform, BrainScope is pioneering the development of digital biomarkers to transform how brain injuries and neurological diseases are assessed and managed. To learn more, visit brainscope.com and follow the company on LinkedIn, X and Instagram.
For media inquiries, please contact:
Roxan Olivas
Lotos Nile
520-954-1634
roxan@lotosnile.com
